The Safety of Antirheumatic Drugs.

Mucke, Johanna; Simon, Hans-Uwe; Burmester, Gerd Rüdiger (2022). The Safety of Antirheumatic Drugs. Deutsches Ärzteblatt international, 119(6), pp. 81-87. Deutscher Ärzte-Verlag 10.3238/arztebl.m2022.0064

[img] Text
Simon_The_Safety_of_Antirheumatic_Drugs_DE.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (910kB)

BACKGROUND

Drug therapy for rheumatic diseases has changed fundamentally in recent decades with the introduction of many new agents. As these drugs may have to be taken for many years, and many of them are of similar efficacy, their safety profiles play an important role in therapeutic decisionmaking.

METHODS

This review is based on pertinent literature retrieved by a selective search on the safety profiles of selected antirheumatic drugs.

RESULTS

Non-steroidal antirheumatic drugs, glucocorticoids, conventional disease-modifying drugs such as methotrexate, biological agents, and janus kinase (JAK) inhibitors are all used to treat rheumatic diseases. Register and trial data show that antirheumatic treatments are relatively safe. Infections, in particular, are much less common than initially expected. Cortisone administration is an exception because of its severe long-term sequelae. Biological agents are associated with severe infectious events at a rate of 4-5 events per 100 patient years. Screening before treatment with biological agents has been shown to lower the rate of tuberculosis from 564 to 95 cases per 100 000 patient years. JAK inhibitors have a good safety profile, with respect to infections as well, but there is evidence of their association with cardiovascular problems, malignancies, and thrombosis.

CONCLUSION

A suitable, safe antirheumatic drug can be chosen for each patient in consideration of individual risk profiles. Regular monitoring enables the early detection of adverse effects. The risk profile of JAK inhibitors, in particular, will be studied in further trials.

Item Type:

Journal Article (Review Article)

Division/Institute:

04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Pharmacology

UniBE Contributor:

Simon, Hans-Uwe

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1866-0452

Publisher:

Deutscher Ärzte-Verlag

Language:

German

Submitter:

Celine Joray

Date Deposited:

13 Jan 2023 15:53

Last Modified:

13 Jan 2023 23:29

Publisher DOI:

10.3238/arztebl.m2022.0064

PubMed ID:

34918622

BORIS DOI:

10.48350/176839

URI:

https://boris.unibe.ch/id/eprint/176839

Actions (login required)

Edit item Edit item
Provide Feedback